New therapies for immune thrombocytopenic purpura

Purpose of review The treatment landscape of immune thrombocytopenic purpura has the potential for dramatic change in the near future as promising new agents and adaptions of older therapies enter clinical study. An update on the status of current research in immune thrombocytopenic purpura and a preview of agents in development are provided here. Recent findings The recent literature shows a multitude of strategies employed in the treatment of immune thrombocytopenic purpura. These therapies under active investigation include the use of B-cell-depending monoclonal antibody rituximab, higher doses of dexamethasone and anti-D immunoglobin, and thrombopoiesis-stimulating agents that are in early clinical development. Summary Clinical investigation of novel therapies in immune thrombocytopenic purpura is undergoing a revolution that has the potential to change the standard of care. While older therapies are experiencing a rebirth by being given a new spin, newer agents such as thrombopoietins are showing difficult significant promise.